Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Conjupro Biotherapeutics, Inc.
Kivu Bioscience Inc.
BeOne Medicines
Eli Lilly and Company
NiKang Therapeutics, Inc.
MacroGenics
SystImmune Inc.
SN BioScience
Boundless Bio, Inc.
AbbVie
Janux Therapeutics
NiKang Therapeutics, Inc.
University of Virginia
Theratechnologies
Sotio Biotech Inc.
Carisma Therapeutics Inc
Vincerx Pharma, Inc.
AstraZeneca
Rhizen Pharmaceuticals SA
Xencor, Inc.
HiberCell, Inc.
Syros Pharmaceuticals
AstraZeneca
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
AbbVie
AbbVie
Incyte Corporation
Incyte Corporation
AstraZeneca
Abramson Cancer Center at Penn Medicine
Celgene
PharmaMar
University of Wisconsin, Madison
AbbVie
Pfizer
Merrimack Pharmaceuticals
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Northwestern University
Santa Maria Biotherapeutics
University of Southern California
Northwestern University
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)